The trial will be testing if it “works “ .
A clear Response & Remission of the actual (breast , ovarian etc also ) cancer cells .
The following -on AML R/R trial just adds to great amount of previous work, .. done better and seeking greater effectiveness again now .
MRD +ve is where bisantrene can really make a difference though to save lives & give patients their best survival chances before their marrow transplant if possible. This is incredibly exciting - wonderful to get bisantrene into the oncology armamentarium.
We are told the IND is now well- progressed . (for the FDA - and US trials base )
All evidence already says ~ Yes bisantrene will work , this is actually known .
It’s the dosages as well ( also really known or can be determined now ) ; & the combinations that will be tested for efficacy & real effectiveness and of course safety .
But any combination treatment with Bisantrene will already be with extensively prior tested agents & testing together and with knowledge of & targeting synergies — *always with the aim for best specificity against the patients cancer. *
This is what it’s about. Treatment is very much lead by real knowledge of likely effectiveness as I’m sure you also realise .
Importantly - Not in question : Safety and ethics, & that is real needed benefit to be gained treating cancers where nothing else is as effective and where these patients will die with only the existing standard care to hand - as likelihood, and new oncology treatments are needed . Bisantrene really has a place here .
It is not an experiment or about applying logic.
Cannot be like this in medical research. Must be evidence based , beyond safety and effectiveness and efficacy proving extensively- before ever goes into forming a broad treatment phase trial .
The FTO protein targeting by bisantrene is pivotal and seems also to be Fact . Now that it is known that this is a likelihood for ‘why’ bisantrene has always been additionally more effective against many difficult to treat cancers , where the standard anthracyclines have not succeeded in fully eliminating the cancer - including breast cancer , ovarian , bladder , ‘progressed ‘ , refractory AML , even brain / liver cancers/ kidney cancers
- Forums
- ASX - By Stock
- RAC
- RAC - Charts & Price Action
RAC - Charts & Price Action, page-1048
- There are more pages in this discussion • 19,885 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.23 |
Change
0.010(0.82%) |
Mkt cap ! $201.9M |
Open | High | Low | Value | Volume |
$1.22 | $1.25 | $1.19 | $68.14K | 55.42K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1939 | $1.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.23 | 3498 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1939 | 1.205 |
1 | 1365 | 1.200 |
1 | 410 | 1.195 |
1 | 808 | 1.190 |
2 | 3500 | 1.180 |
Price($) | Vol. | No. |
---|---|---|
1.230 | 3498 | 1 |
1.235 | 425 | 1 |
1.260 | 7211 | 1 |
1.265 | 415 | 1 |
1.275 | 1300 | 1 |
Last trade - 12.32pm 08/05/2024 (20 minute delay) ? |
|
|||||
Last
$1.21 |
  |
Change
0.010 ( 1.68 %) |
|||
Open | High | Low | Volume | ||
$1.22 | $1.26 | $1.20 | 11491 | ||
Last updated 12.59pm 08/05/2024 ? |
Featured News
RAC (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online